<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140231</url>
  </required_header>
  <id_info>
    <org_study_id>2002P000049</org_study_id>
    <secondary_id>2M01RR001032-30</secondary_id>
    <secondary_id>5R01DK058785-07</secondary_id>
    <nct_id>NCT00140231</nct_id>
  </id_info>
  <brief_title>Role of Leptin in the Neuroendocrine and Immune Response to Fasting</brief_title>
  <official_title>Role of Leptin in the Neuroendocrine and Immune Response to Fasting in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to determine whether giving leptin (r-metHuLeptin) to a
      person when he or she is fasting will reverse changes in metabolism, and hormone levels, and
      immune function associated with fasting, which decreases leptin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to
      decrease appetite and increase energy use. Leptin levels usually go down with fasting. This
      study will evaluate the secretion of an investigational agent called leptin in lean and
      overweight individuals while fasting and investigate the potential role of leptin as a
      regulator of immune function and mediator of the neuroendocrine response to food deprivation
      in humans. Data derived from these studies will provide insights into the mechanisms
      underlying altered hormone levels and immune function in malnutrition and obesity and thus
      may provide the basis for future therapeutic interventions for obesity.

      Comparison: fed state vs. fasting state vs. fasting + leptin state
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol</measure>
    <time_frame>four days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ACTH Mean Level</measure>
    <time_frame>4 days</time_frame>
    <description>Response of ACTH to leptin administration in fed and fasting state from baseline was measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune Function CD3 Count</measure>
    <time_frame>4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>%Fat Mass</measure>
    <time_frame>four days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(RMR)</measure>
    <time_frame>four days</time_frame>
    <description>Resting Metabolic rate using calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic Function</measure>
    <time_frame>four days</time_frame>
    <description>aldosterone level were measured on day 4 in response to leptin in fed and fasting states and compared with baseline level on day 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Metreleptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>r-metHuLeptin self-administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, administered in same method as active arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-metHuLeptin</intervention_name>
    <description>recombinant human leptin</description>
    <arm_group_label>Metreleptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>metreleptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (no active drug)</description>
    <arm_group_label>Metreleptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy lean women (with body mass indices [BMI] &lt; 25 kg/m2)

          -  Overweight otherwise healthy men (with BMI &gt; 27 kg/m2)

          -  Overweight otherwise healthy women (with BMI &gt; 27 kg/m2).

        Exclusion Criteria:

          -  A history of any illness that may affect the concentrations of the hormones to be
             studied, e.g. infectious diseases, renal or hepatic failure, type 1 or type 2 diabetes
             mellitus, cancer or lymphoma, hypogonadism, malabsorption or malnourishment, hypo- or
             hyperthyroidism, hypercortisolism, alcoholism or drug abuse, anemia, or eating
             disorder

          -  On medications known to affect the hormones to be measured (glucocorticoids,
             anti-seizure medications, and thyroid hormones)

          -  A known history of anaphylaxis or anaphylactoid-like reactions, or a known
             hypersensitivity to E. coli derived proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos S Mantzoros, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bidmc.org/Research/Departments/Medicine/Divisions/Endocrinology/Laboratories/MantzorosLab.aspx</url>
    <description>Click here for more information about the Mantzoros Research Group.</description>
  </link>
  <link>
    <url>http://www.bidmc.harvard.edu</url>
    <description>Click here for more information about Beth Israel Deaconess Medical Center.</description>
  </link>
  <reference>
    <citation>Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003 May;111(9):1409-21.</citation>
    <PMID>12727933</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <results_first_submitted>December 29, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>leptin</keyword>
  <keyword>fasting</keyword>
  <keyword>reproductive</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>immune function</keyword>
  <keyword>energy deficiency associated with short-term fasting</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iso Fed, Then Fasting w/ Metreleptin, Then Fasting w/ Placebo</title>
          <description>Six young, healthy, and lean women (age, 22.8,; BMI,21.7kg/m2) who were eumenor- rheic were enrolled in a clinical researchcenterâ€“ based, randomized, cross-over interventional study involving three separate 5-day-long inpatient admissions (22). Six subjects with a cross-over design, enabling paired comparisons, would provide 80% power to detect a difference of 1.4 SD between different conditionsat the conventional
a=0.05 level. In thefirst admission, the subjects were studied in the isocaloric fed state, whereas in the following two admissions the subjects were studied in the prolonged fasting state for 72 h and were randomized to receive either placebo or metreleptin at replacement doses. A cross-over to the opposite arm took place in the later admission so that all six subjects received both placebo and metreleptin.
r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
        </group>
        <group group_id="P2">
          <title>Iso Fed, Then Fasting w/ Placebo, Then Fasting w/ Met</title>
          <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Fed State 1 Day- day5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 8weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Fasting State 3 Days With Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout 8 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fasting State With Leptin and Crossover</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iso Fed, Then Fasting w/ Metreleptin, Then Fasting w/ Placebo</title>
          <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
        </group>
        <group group_id="B2">
          <title>Iso Fed, Then Fasting w/ Placebo, Then Fasting w/ Metreleptin</title>
          <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="5"/>
                    <measurement group_id="B2" value="25" spread="5"/>
                    <measurement group_id="B3" value="25.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cortisol</title>
        <time_frame>four days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol</title>
          <units>ug/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="0.9"/>
                    <measurement group_id="O2" value="16.9" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACTH Mean Level</title>
        <description>Response of ACTH to leptin administration in fed and fasting state from baseline was measured</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>ACTH Mean Level</title>
          <description>Response of ACTH to leptin administration in fed and fasting state from baseline was measured</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline fed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.48" spread="1.28"/>
                    <measurement group_id="O2" value="9.33" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.89" spread="2.01"/>
                    <measurement group_id="O2" value="8.74" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immune Function CD3 Count</title>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Function CD3 Count</title>
          <units>cells/ul</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="185"/>
                    <measurement group_id="O2" value="838" spread="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>%Fat Mass</title>
        <time_frame>four days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>%Fat Mass</title>
          <units>fat%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="2.2"/>
                    <measurement group_id="O2" value="29.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(RMR)</title>
        <description>Resting Metabolic rate using calorimetry</description>
        <time_frame>four days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>(RMR)</title>
          <description>Resting Metabolic rate using calorimetry</description>
          <units>kcal/d</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.344" spread="34"/>
                    <measurement group_id="O2" value="1.352" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Autonomic Function</title>
        <description>aldosterone level were measured on day 4 in response to leptin in fed and fasting states and compared with baseline level on day 1</description>
        <time_frame>four days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin</title>
            <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
          </group>
        </group_list>
        <measure>
          <title>Autonomic Function</title>
          <description>aldosterone level were measured on day 4 in response to leptin in fed and fasting states and compared with baseline level on day 1</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" spread="27.0"/>
                    <measurement group_id="O2" value="112" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 1 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" spread="11.7"/>
                    <measurement group_id="O2" value="66.0" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metreleptin</title>
          <description>r-metHuLeptin self-administered subcutaneously
r-metHuLeptin: recombinant human leptin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo, administered in same method as active arm.
placebo: placebo (no active drug)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study is confined to lean, healthy female subjects; therefore, our results should not be generalized to male, obese,or diabetic subjects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christos Mantzoros</name_or_title>
      <organization>BIDMC</organization>
      <phone>6176678633</phone>
      <email>cmantzor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

